Phospho-PKMYT1 (S83) Antibody

What is the biological function of PKMYT1 in cell cycle regulation?

PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1) functions primarily as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylating CDK1 kinase when complexed to cyclins. It predominantly mediates phosphorylation of CDK1 at Thr-14, and may also be involved in phosphorylation at Tyr-15, though this tyrosine kinase activity remains unclear and could be indirect. Beyond cell cycle regulation, PKMYT1 also plays a role in Golgi fragmentation, highlighting its multifunctional nature in cellular processes .

How does S83 phosphorylation potentially affect PKMYT1 function compared to other phosphorylation sites?

While specific information about S83 phosphorylation of PKMYT1 is limited in current literature, phosphorylation at specific serine residues generally serves as a regulatory mechanism for kinase activity. Similar to how RSK2 phosphorylates ASK1 at S83 to inhibit its function (as seen in other kinase systems), phosphorylation of PKMYT1 at S83 may modulate its activity, stability, localization, or interactions with binding partners . Understanding S83 phosphorylation could provide insights into how PKMYT1 is regulated, particularly in cancer contexts where its expression is elevated.

What experimental models are most suitable for studying PKMYT1 phosphorylation?

Based on recent studies, human PDAC cell lines (such as Pa-Tu-8988T, YAPC, and BxPc3) and primary cultured cells (PDAC-CN1, PDAC-CN2) have proven particularly effective for studying PKMYT1 function . These models demonstrate clear phenotypic responses to PKMYT1 manipulation, making them suitable for phosphorylation studies. For in vivo investigations, xenograft models in nude mice have successfully demonstrated the consequences of PKMYT1 knockout, suggesting their utility for phosphorylation studies as well . When selecting experimental models, consider both KRAS-mutant and KRAS-wild-type cell lines to account for potential differences in signaling contexts.

What are the optimal conditions for detecting Phospho-PKMYT1 (S83) in Western blot applications?

For optimal Western blot detection of phosphorylated proteins like Phospho-PKMYT1 (S83), researchers should implement several critical steps. First, rapid sample collection and immediate lysis in phosphatase inhibitor-containing buffers is essential to preserve phosphorylation status. Based on protocols used for similar phospho-specific antibodies, recommended dilutions typically range from 1:500 to 1:2000 in 5% BSA/TBST solution. Nitrocellulose membranes generally yield better results than PVDF for phospho-epitopes. Include positive controls (such as cells treated with phosphatase inhibitors) and negative controls (samples treated with lambda phosphatase) to validate specificity. For PKMYT1 specifically, detection may be enhanced by enriching the protein through immunoprecipitation prior to Western blotting, as demonstrated in studies of other phosphorylated kinases .

What approaches can verify phospho-specificity of the Phospho-PKMYT1 (S83) Antibody?

To rigorously verify antibody phospho-specificity, implement a multi-tiered validation strategy. First, conduct parallel Western blots with both phospho-specific and total PKMYT1 antibodies to confirm that phosphorylation-induced mobility shifts are detected appropriately. Second, perform phosphatase treatment assays, where sample aliquots treated with lambda phosphatase should show diminished or absent signal with the phospho-specific antibody while maintaining detection with total protein antibody. Third, utilize CRISPR-Cas9 knockout controls, as demonstrated in PKMYT1 studies, to confirm signal specificity . Finally, consider peptide competition assays using phosphorylated versus non-phosphorylated peptides encompassing the S83 region. For ultimate validation, test the antibody on samples expressing wild-type PKMYT1 versus S83A mutants that cannot be phosphorylated at this position.

How should cell culture conditions be optimized when studying PKMYT1 phosphorylation during cell cycle transitions?

When investigating PKMYT1 phosphorylation states during cell cycle transitions, synchronization protocols are critical for obtaining interpretable results. For G2/M transition studies where PKMYT1 activity is particularly relevant, thymidine-nocodazole block protocols have proven effective in related research . Cell density significantly impacts phosphorylation states; maintain cultures at 60-80% confluence to avoid contact inhibition effects on cell cycle. Serum starvation (0.1% FBS for 24 hours) followed by serum restoration effectively synchronizes cells in G0/G1, allowing for subsequent time course analysis through S and G2/M phases. When harvesting samples, implement rapid processing with pre-chilled buffers containing both phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) and protease inhibitors to preserve phosphorylation status. Monitor synchronization efficiency through parallel flow cytometry analysis for cell cycle distribution, as demonstrated in PLK1 studies related to PKMYT1 function .

How can Phospho-PKMYT1 (S83) Antibody be used to elucidate PKMYT1's role in cancer progression?

To leverage Phospho-PKMYT1 (S83) Antibody for investigating cancer progression mechanisms, researchers should implement a multi-dimensional approach integrating clinical and experimental systems. Begin with immunohistochemical analysis of tissue microarrays containing matched primary and metastatic samples to establish correlation between phosphorylation status and disease progression, similar to approaches used for total PKMYT1 . For functional studies, employ the antibody in phosphorylation time-course experiments following treatments with PKMYT1 inhibitors like RP-6306, which has demonstrated efficacy in PDAC models . Combine this with downstream analyses of CDK1 phosphorylation at Thr14 and Tyr15 to establish mechanistic links. Additionally, co-immunoprecipitation studies with the antibody can identify phosphorylation-dependent interaction partners, potentially revealing novel signaling nodes. For in vivo relevance, analyze phosphorylation status in patient-derived xenograft models before and after treatment with targeted therapies to correlate phosphorylation dynamics with treatment response.

What experimental design would best address the potential relationship between PKMYT1 phosphorylation and PLK1 regulation?

Recent findings indicating that PKMYT1 regulates PLK1 stability and phosphorylation suggest a complex interplay between these kinases . To investigate this relationship through the lens of PKMYT1 phosphorylation, design experiments that manipulate phosphorylation status while monitoring PLK1 dynamics. First, establish baseline correlation through co-immunoprecipitation studies using Phospho-PKMYT1 (S83) Antibody to determine if phosphorylation status affects PLK1 binding. Next, generate phospho-mimetic (S83D) and phospho-null (S83A) PKMYT1 mutants and assess their impact on PLK1 stability through cycloheximide chase assays, similar to those demonstrating PKMYT1's effect on PLK1 half-life . Include proteasome inhibitors like MG132 to determine if phosphorylation affects the proteasome-mediated degradation pathway. Complement these approaches with in vitro kinase assays using recombinant proteins to assess whether S83 phosphorylation alters PKMYT1's ability to phosphorylate PLK1. Finally, conduct functional studies examining how these mutations affect cell cycle progression, particularly G2/M transition, through flow cytometry analysis.

How might Phospho-PKMYT1 (S83) Antibody be utilized to evaluate therapeutic responses to PKMYT1 inhibitors?

Developing Phospho-PKMYT1 (S83) Antibody as a biomarker for therapeutic response requires systematic validation across multiple experimental contexts. Design a comprehensive protocol beginning with in vitro dose-response studies correlating inhibitor concentrations (e.g., RP-6306) with changes in S83 phosphorylation across a panel of cancer cell lines with varying PKMYT1 expression levels . Establish temporal dynamics by conducting time-course experiments to determine the relationship between S83 phosphorylation changes and functional outcomes like cell cycle arrest and apoptosis. For translational relevance, implement ex vivo assays using fresh patient-derived tumor samples treated with inhibitors in short-term cultures to assess phosphorylation changes. In in vivo models, collect sequential biopsies from xenografts during treatment to monitor phosphorylation as a pharmacodynamic marker. This approach should be validated across both cell line-derived xenografts and patient-derived xenografts as used in PKMYT1 inhibitor studies . Additionally, investigate potential compensatory phosphorylation changes at other sites that might contribute to resistance mechanisms.

How can researchers address inconsistent detection of Phospho-PKMYT1 (S83) across different experimental conditions?

Inconsistent detection of phosphorylated proteins represents a common challenge in phospho-antibody applications. When encountering variable Phospho-PKMYT1 (S83) detection, implement a systematic troubleshooting approach addressing multiple variables. First, examine sample processing procedures—phosphorylation states are notoriously labile, requiring immediate sample denaturation in buffer containing phosphatase inhibitor cocktails (sodium orthovanadate, sodium fluoride, β-glycerophosphate). Second, evaluate antibody validation status through peptide competition assays comparing phosphorylated versus non-phosphorylated S83-containing peptides. Third, consider cell cycle dependency—if S83 phosphorylation occurs primarily during specific cell cycle phases, unsynchronized cultures may show variable signal depending on the proportion of cells in relevant phases . Fourth, assess the impact of culture conditions—serum components contain growth factors that activate various signaling pathways, potentially affecting phosphorylation status. Finally, if inconsistencies persist between cell lines, investigate potential differences in phosphatase expression or activity, as these enzymes rapidly remove phosphate groups and may vary significantly between experimental models.

What analytical approaches can determine if S83 phosphorylation status correlates with PKMYT1's inhibitory effect on CDK1?

To establish a functional correlation between S83 phosphorylation and PKMYT1's canonical activity of inhibiting CDK1, implement a multi-method analytical approach. Begin with temporal analysis, collecting cell samples at defined intervals during cell cycle progression and performing parallel Western blots for Phospho-PKMYT1 (S83), total PKMYT1, and CDK1 phosphorylated at Thr14 and Tyr15 (PKMYT1's known target sites) . Calculate Pearson or Spearman correlation coefficients between S83 phosphorylation intensity and CDK1 phosphorylation levels. Next, generate phospho-mimetic (S83D) and phospho-null (S83A) PKMYT1 mutants and assess their capacity to phosphorylate CDK1 in vitro using recombinant proteins and γ-32P-ATP, similar to in vitro kinase assays used for other phosphorylation studies . Complement biochemical data with functional cell cycle analysis using flow cytometry to determine if cells expressing these mutants show differential G2/M transition kinetics. For definitive mechanistic insight, perform structural studies examining whether S83 phosphorylation induces conformational changes in PKMYT1's kinase domain, potentially affecting ATP binding or substrate recognition.

How might the phosphorylation status of PKMYT1 at S83 influence its potential as a biomarker for cancer prognosis?

Given that higher PKMYT1 expression correlates with worse prognosis in PDAC patients , investigating whether S83 phosphorylation status provides additional prognostic value represents a compelling research direction. Design a comprehensive clinical validation study beginning with retrospective analysis of tissue microarrays from patients with known outcomes, staining for both total and phospho-S83 PKMYT1. Calculate hazard ratios through multivariate Cox regression analysis to determine if phosphorylation status provides independent prognostic information beyond total expression. For mechanistic insights, isolate primary tumor cells from patients and assess correlation between S83 phosphorylation levels and functional phenotypes such as chemoresistance, migration capacity, and stem-like properties. Develop a standardized immunohistochemical scoring system similar to those used for other phospho-biomarkers, with clear cutoff values for "high" versus "low" phosphorylation determined through receiver operating characteristic (ROC) curve analysis. Finally, explore potential heterogeneity of phosphorylation within tumors through multiplexed immunofluorescence, examining correlation with histological features and markers of tumor aggressiveness.

What experimental approaches would best elucidate the impact of TP53 function on PKMYT1 phosphorylation and inhibition sensitivity?

Recent findings indicate that TP53 function modulates sensitivity to PKMYT1 inhibition , suggesting a potential relationship between TP53 status and PKMYT1 regulation. To investigate this connection specifically at the phosphorylation level, design comparative studies using isogenic cell line pairs differing only in TP53 status. First, establish baseline S83 phosphorylation levels in TP53 wild-type versus null backgrounds through Western blot analysis. Next, conduct time-course experiments following DNA damage induction (using agents like doxorubicin or ionizing radiation) to determine if TP53 activation affects PKMYT1 phosphorylation dynamics. Investigate potential direct regulation by performing chromatin immunoprecipitation to assess if TP53 binds to the promoters of kinases that might phosphorylate PKMYT1 at S83. Implement CRISPR-Cas9 screens to identify mediators of differential PKMYT1 inhibitor sensitivity in TP53 mutant versus wild-type backgrounds, similar to the genome-wide CRISPR screens that identified PKMYT1 as a vulnerability in PDAC . Finally, analyze transcriptional responses to PKMYT1 inhibition in both contexts through RNA-sequencing to identify differentially regulated pathways that might explain the synthetic lethality relationship.

What methodological innovations could advance our understanding of how PKMYT1 phosphorylation affects its interaction with PRKDC in therapeutic contexts?

The identification of PRKDC activation as a modulator of sensitivity to PKMYT1 inhibition highlights the need for advanced methods to study this interaction in a phosphorylation-dependent manner. Develop proximity-based protein interaction assays such as BioID or APEX2 using PKMYT1 phospho-mimetic (S83D) and phospho-null (S83A) mutants as baits to compare interactomes under normal and DNA damage conditions. Implement live-cell FRET (Förster Resonance Energy Transfer) biosensors to monitor real-time interactions between PKMYT1 and PRKDC, assessing how phosphorylation status affects their association dynamics during cell cycle progression and following DNA damage. For structural insights, utilize hydrogen-deuterium exchange mass spectrometry to identify regions of PKMYT1 whose solvent accessibility changes upon phosphorylation, potentially revealing interaction interfaces. Functionally validate findings through in vitro kinase assays testing whether S83 phosphorylation affects PKMYT1's ability to be phosphorylated by PRKDC or vice versa, similar to approaches used in ASK1 phosphorylation studies . Finally, explore therapeutic implications by testing combinations of PKMYT1 inhibitors and PRKDC inhibitors in 3D organoid cultures derived from primary tumors, assessing whether S83 phosphorylation status predicts synergistic versus antagonistic interactions.